Details for New Drug Application (NDA): 218354
✉ Email this page to a colleague
NDA 218354 describes EDARAVONE, which is a drug marketed by Dr Reddys, Gland Pharma Ltd, Hikma, and Long Grove Pharms, and is included in four NDAs. It is available from three suppliers. Additional details are available on the EDARAVONE profile page.
The generic ingredient in EDARAVONE is edaravone. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.
The generic ingredient in EDARAVONE is edaravone. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.
Summary for 218354
| Tradename: | EDARAVONE |
| Applicant: | Long Grove Pharms |
| Ingredient: | edaravone |
| Patents: | 0 |
Suppliers and Packaging for NDA: 218354
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EDARAVONE | edaravone | SOLUTION;INTRAVENOUS | 218354 | ANDA | Long Grove Pharmaceuticals, LLC | 81298-7050 | 81298-7050-3 | 2 BAG in 1 CARTON (81298-7050-3) / 100 mL in 1 BAG (81298-7050-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 30MG/100ML (0.3MG/ML) | ||||
| Approval Date: | May 6, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
